Significant ETF Inflows: SPLG, XOM, WFC, ABT
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Source: NASDAQ.COM
SPLG Share Price Analysis: SPLG's current share price is $75.74, with a 52-week low of $56.6699 and a high of $76.025.
Understanding ETFs: Exchange traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand.
Monitoring ETF Flows: Weekly monitoring of shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (old units destroyed), impacting their underlying holdings.
Author's Perspective: The opinions expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 87.540
Low
136.00
Averages
148.11
High
169.00
Current: 87.540
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott Laboratories Attracts Income Investors with 3% Yield
- Dividend Appeal: Abbott Laboratories offers an attractive yield nearing 3%, appealing to income-focused investors while navigating rising cost pressures amidst ongoing business growth.
- Dividend King Status: With over 50 consecutive years of dividend increases, Abbott's record as a Dividend King enhances investor confidence in its long-term value proposition within the healthcare sector.
- Market Performance Analysis: While Abbott's stock isn't considered a bargain, its performance remains noteworthy, particularly when compared to other high-return stocks, indicating robust investment potential.
- Investment Recommendations: Although Abbott was not included in The Motley Fool Stock Advisor's top stock picks, its established position in the healthcare industry and history of dividend growth still make it a noteworthy investment consideration.
See More
AbbVie and Realty Income's Stable Dividend Prospects
- AbbVie Dividend Growth: AbbVie's board declared a quarterly cash dividend of $1.73 per share, payable on May 15, 2026, demonstrating the company's ability to increase dividends for 54 consecutive years, even amidst patent expiration challenges, while maintaining robust business growth.
- Dividend Yield Performance: AbbVie's forward dividend yield stands above 3.3%, although below its historical average, yet its solid stock price appreciation and 33% dividend growth over the past five years indicate effective inflation management.
- Realty Income Stability: Realty Income has paid dividends for 670 consecutive quarters since going public in 1994, with a forward dividend yield exceeding 5%, showcasing its ability to generate steady cash flow and maintain a high occupancy rate of 98.9% even during economic fluctuations.
- Market Growth Potential: Realty Income's total addressable market is estimated at $13 trillion, with $8.5 trillion in Europe, indicating significant growth potential in a highly fragmented market, which suggests the company can continue to provide substantial monthly dividends to investors.
See More
Abbott Laboratories Attracts Income Investors
- Yield Approaching 3%: Abbott Laboratories is currently offering a yield nearing 3%, attracting income-focused investors, and despite rising costs, its ongoing business growth remains noteworthy.
- Dividend King Status: As a Dividend King, Abbott has increased its dividends for over 50 consecutive years, a record that not only boosts investor confidence but also indicates the company's strong cash flow and profitability capabilities.
- Market Price Analysis: Market prices as of April 27, 2026, indicate that while the stock isn't a screaming bargain, its stable dividends and growth potential still render it a valuable investment in the healthcare sector.
- Long-Term Growth Potential: Despite current cost pressures, Abbott's business growth and dividend policy suggest strong long-term growth potential, making it a suitable focus for long-term investors.
See More
Executive Stock Transactions Overview
- Executive Stock Purchase: Daniel J. Starks, a director at Abbott Laboratories, acquired 10,000 shares for $926,537 on April 27, 2026, increasing his total holdings to 6.75 million shares, indicating confidence in the company despite a 29% stock price decline this year.
- CFO Transactions: EVP and CFO Philip P. Boudreau disclosed an open-market purchase of 2,200 shares at $91.50 each on April 23, 2026, holding 71,172 shares directly after the transaction, reflecting executive recognition of the company's value.
- Investment Amid Market Decline: S&P Global CEO Martina Cheung purchased 2,322 shares at an average price of $429.93 on April 29, 2026, totaling nearly $1 million, increasing her holdings to 27,518 shares, showcasing a strategy of buying during market lows.
- Multiple Executive Transactions: Executives from International Paper and Charter also made significant stock purchases, acquiring 10,000 shares and 6,936 shares respectively, indicating optimism about their companies' prospects in the current market environment.
See More
Abbott Laboratories: Attractive Dividend Investment Opportunity
- Price Dip Opportunity: Abbott Laboratories' stock has fallen 30% over the past year, currently priced at $89.46, presenting an opportunity for investors to buy on the dip and potentially achieve long-term returns.
- Acquisition-Driven Growth: The company completed a $21 billion acquisition of Exact Sciences in Q1, which is expected to enhance revenue through new products like Cologuard, particularly in the colorectal cancer screening market, thereby expanding its market share.
- Innovative Product Line: Abbott's FreeStyle Libre continuous glucose monitoring devices have been a major growth driver, and the launch of new products like Lingo and Libre Rio will help the company penetrate underdeveloped markets, catering to more diabetes patients.
- Stable Dividend Returns: As a Dividend King, Abbott Laboratories has increased its dividend for 50 consecutive years, with a current yield of 2.8%, significantly above the S&P 500's 1.1%, providing investors with a reliable cash flow.
See More
Abbott Laboratories Stock Down 30%: A Long-Term Buy Opportunity
- Stock Price Decline: Abbott Laboratories' stock has fallen 30% over the past year, primarily due to slow growth in its nutrition and diagnostics segments, with only 3.7% comparable sales growth in Q1, which has impacted investor confidence.
- Acquisition-Driven Growth: The company completed a $21 billion acquisition of Exact Sciences in Q1, introducing new products like Cologuard for colorectal cancer testing, which is expected to leverage Abbott's strong healthcare presence to drive growth and expand market share.
- Innovative Product Line: Abbott's FreeStyle Libre continuous glucose monitoring devices have been a major growth driver in recent years, and with the CGM market still underpenetrated, the launch of new over-the-counter CGM products like Lingo and Libre Rio will further target populations and enhance sales potential.
- Dividend Attractiveness: As a
See More
Abbott Laboratories Attracts Income Investors with 3% Yield
- Dividend Appeal: Abbott Laboratories offers an attractive yield nearing 3%, appealing to income-focused investors while navigating rising cost pressures amidst ongoing business growth.
- Dividend King Status: With over 50 consecutive years of dividend increases, Abbott's record as a Dividend King enhances investor confidence in its long-term value proposition within the healthcare sector.
- Market Performance Analysis: While Abbott's stock isn't considered a bargain, its performance remains noteworthy, particularly when compared to other high-return stocks, indicating robust investment potential.
- Investment Recommendations: Although Abbott was not included in The Motley Fool Stock Advisor's top stock picks, its established position in the healthcare industry and history of dividend growth still make it a noteworthy investment consideration.
See More
AbbVie and Realty Income's Stable Dividend Prospects
- AbbVie Dividend Growth: AbbVie's board declared a quarterly cash dividend of $1.73 per share, payable on May 15, 2026, demonstrating the company's ability to increase dividends for 54 consecutive years, even amidst patent expiration challenges, while maintaining robust business growth.
- Dividend Yield Performance: AbbVie's forward dividend yield stands above 3.3%, although below its historical average, yet its solid stock price appreciation and 33% dividend growth over the past five years indicate effective inflation management.
- Realty Income Stability: Realty Income has paid dividends for 670 consecutive quarters since going public in 1994, with a forward dividend yield exceeding 5%, showcasing its ability to generate steady cash flow and maintain a high occupancy rate of 98.9% even during economic fluctuations.
- Market Growth Potential: Realty Income's total addressable market is estimated at $13 trillion, with $8.5 trillion in Europe, indicating significant growth potential in a highly fragmented market, which suggests the company can continue to provide substantial monthly dividends to investors.
See More
Abbott Laboratories Attracts Income Investors
- Yield Approaching 3%: Abbott Laboratories is currently offering a yield nearing 3%, attracting income-focused investors, and despite rising costs, its ongoing business growth remains noteworthy.
- Dividend King Status: As a Dividend King, Abbott has increased its dividends for over 50 consecutive years, a record that not only boosts investor confidence but also indicates the company's strong cash flow and profitability capabilities.
- Market Price Analysis: Market prices as of April 27, 2026, indicate that while the stock isn't a screaming bargain, its stable dividends and growth potential still render it a valuable investment in the healthcare sector.
- Long-Term Growth Potential: Despite current cost pressures, Abbott's business growth and dividend policy suggest strong long-term growth potential, making it a suitable focus for long-term investors.
See More
Executive Stock Transactions Overview
- Executive Stock Purchase: Daniel J. Starks, a director at Abbott Laboratories, acquired 10,000 shares for $926,537 on April 27, 2026, increasing his total holdings to 6.75 million shares, indicating confidence in the company despite a 29% stock price decline this year.
- CFO Transactions: EVP and CFO Philip P. Boudreau disclosed an open-market purchase of 2,200 shares at $91.50 each on April 23, 2026, holding 71,172 shares directly after the transaction, reflecting executive recognition of the company's value.
- Investment Amid Market Decline: S&P Global CEO Martina Cheung purchased 2,322 shares at an average price of $429.93 on April 29, 2026, totaling nearly $1 million, increasing her holdings to 27,518 shares, showcasing a strategy of buying during market lows.
- Multiple Executive Transactions: Executives from International Paper and Charter also made significant stock purchases, acquiring 10,000 shares and 6,936 shares respectively, indicating optimism about their companies' prospects in the current market environment.
See More
Abbott Laboratories: Attractive Dividend Investment Opportunity
- Price Dip Opportunity: Abbott Laboratories' stock has fallen 30% over the past year, currently priced at $89.46, presenting an opportunity for investors to buy on the dip and potentially achieve long-term returns.
- Acquisition-Driven Growth: The company completed a $21 billion acquisition of Exact Sciences in Q1, which is expected to enhance revenue through new products like Cologuard, particularly in the colorectal cancer screening market, thereby expanding its market share.
- Innovative Product Line: Abbott's FreeStyle Libre continuous glucose monitoring devices have been a major growth driver, and the launch of new products like Lingo and Libre Rio will help the company penetrate underdeveloped markets, catering to more diabetes patients.
- Stable Dividend Returns: As a Dividend King, Abbott Laboratories has increased its dividend for 50 consecutive years, with a current yield of 2.8%, significantly above the S&P 500's 1.1%, providing investors with a reliable cash flow.
See More
Abbott Laboratories Stock Down 30%: A Long-Term Buy Opportunity
- Stock Price Decline: Abbott Laboratories' stock has fallen 30% over the past year, primarily due to slow growth in its nutrition and diagnostics segments, with only 3.7% comparable sales growth in Q1, which has impacted investor confidence.
- Acquisition-Driven Growth: The company completed a $21 billion acquisition of Exact Sciences in Q1, introducing new products like Cologuard for colorectal cancer testing, which is expected to leverage Abbott's strong healthcare presence to drive growth and expand market share.
- Innovative Product Line: Abbott's FreeStyle Libre continuous glucose monitoring devices have been a major growth driver in recent years, and with the CGM market still underpenetrated, the launch of new over-the-counter CGM products like Lingo and Libre Rio will further target populations and enhance sales potential.
- Dividend Attractiveness: As a
See More
